Innovating Works

MgSafe

Financiado
Promoting patient safety by a novel combination of imaging technologies for biod...
Promoting patient safety by a novel combination of imaging technologies for biodegradable magnesium implants Biomedical imaging has gained a significant technological push and is the mainstay for diag-nosis and therapy monitoring. Still, imaging is yet not optimized for the new class of biode-gradable Mg-based implants. MgSafe addresses... Biomedical imaging has gained a significant technological push and is the mainstay for diag-nosis and therapy monitoring. Still, imaging is yet not optimized for the new class of biode-gradable Mg-based implants. MgSafe addresses this point by training 15 ESRs in both, imag-ing and implant technologies. All ESRs will develop their individual Personal Learning Envi-ronment (PLE) and be trained based on the T-skills concept in technologies and transferable skills relevant for their career development and prepared to take over leadership positions in an area of tremendous research promises and clinical relevance where the lack for experts is severe and very well recognized. The ESRs will quantify the physical impact and suitability of a variety of modalities on Mg implants. Highly sophisticated imaging techniques (nano and µCT, MRT, PET, USPA, IR) will be developed beyond the forefront of medical device production in vivo and with in situ label-ling options to deliver non-invasively data on different time and length scales of the body reac-tion and material behavior during Mg degradation with a precision and plethora of details which is currently not available. Two Mg-alloys and CE-certified Mg-implants will be studied in rats and sheep. Dummy studies will be performed in parallel (following ASTM rules). The ob-tained multimodal imaging data will be combined with molecular biological/biochemical analy-sis, thereby increasing the information about physiological changes without using additional animals. An additional dimension will be added by the analysis of explants to obtain highest resolution chemical and material science data. All relevant biological and chemical in vivo and ex vivo data will be merged by computational 3D methods, simulations and machine learning approaches. The combination of these results will not only allow for an upscaling of the pro-cesses towards humans but will also deliver valuable data in terms of patient safety. ver más
30/09/2022
HEREON
4M€
Duración del proyecto: 49 meses Fecha Inicio: 2018-08-20
Fecha Fin: 2022-09-30

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2022-09-30
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
MSCA-ITN-2018: Innovative Training Networks
Cerrada hace 6 años
Presupuesto El presupuesto total del proyecto asciende a 4M€
Líder del proyecto
HELMHOLTZZENTRUM HEREON GMBH No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5